Obesity & Medical Weight Loss: A Physician-Reviewed Guide

Definition

What Is Obesity?

Obesity is a chronic, relapsing disease of excess adiposity that meaningfully impairs health. The American Medical Association formally recognized it as a disease in 2013, joining the World Health Organization, the National Institutes of Health, and the Obesity Medicine Association in classifying it alongside hypertension and type 2 diabetes [4][5].

The condition is defined by what excess fat does to the body — not by appearance. Adipose tissue is an active endocrine organ that secretes hormones (leptin, adiponectin, inflammatory cytokines) and disrupts insulin signaling, blood pressure regulation, reproductive function, and cardiovascular risk. Some clinicians prefer the term Adiposity-Based Chronic Disease (ABCD) to emphasize that obesity is a physiologic, not behavioral, diagnosis.

Critically, obesity is not a failure of willpower. The hormonal and neurologic systems that regulate hunger, satiety, and energy expenditure operate largely below conscious control. This is why diet-and-exercise advice alone produces 5% average weight loss that is regained within 3–5 years in the majority of patients — and why modern obesity medicine layers nutrition, behavior, pharmacotherapy, and, when indicated, surgery into a long-term care framework.

Diagnosis

How Is Obesity Diagnosed?

Body mass index (BMI) is the most widely used screening tool. A BMI of 25–29.9 is classified as overweight; 30–34.9 is class I obesity; 35–39.9 is class II; and 40 or higher is class III (formerly "morbid" obesity) [1][5]. BMI is calculated from height and weight and is useful at the population level, but it is not a diagnosis on its own.

Modern clinical diagnosis adds:

• ·Waist circumference (>35 inches in women, >40 inches in men) as a marker of visceral adiposity and cardiometabolic risk.
• ·Body composition (DEXA, bioelectrical impedance) to distinguish lean from fat mass — relevant for athletes, older adults, and patients on GLP-1 therapy.
• ·Metabolic labs: fasting glucose, hemoglobin A1c, fasting insulin, HOMA-IR, lipid panel including ApoB and Lp(a), liver enzymes, hs-CRP, and TSH.
• ·Hormone panel where indicated (testosterone, estradiol, cortisol, sex hormone–binding globulin) to identify treatable endocrine drivers.

A physician interprets these together. A patient with a BMI of 27 but elevated visceral fat, insulin resistance, and a family history of type 2 diabetes may warrant treatment, while a muscular patient with a BMI of 31 and clean labs may not.

Causes

What Causes Weight Gain?

Weight gain reflects the body defending a higher fat-mass set point — usually for multiple, overlapping reasons:

• ·Genetics. Twin and adoption studies attribute 40–70% of inter-individual variation in body weight to inherited factors influencing appetite, satiety, and resting metabolic rate.
• ·Insulin resistance. As cells become less sensitive to insulin, the pancreas produces more of it; chronically elevated insulin promotes fat storage and blocks fat release. This is often the first measurable change long before blood sugar rises.
• ·Hormonal shifts. Menopause, perimenopause, hypothyroidism, PCOS, low testosterone, and Cushing's syndrome can each meaningfully change body composition and energy balance.
• ·Sleep and circadian disruption. Sleeping fewer than 6 hours per night raises ghrelin (hunger), lowers leptin (satiety), and impairs glucose tolerance — biasing the body toward fat storage.
• ·Chronic stress. Sustained cortisol elevation drives central adiposity, hyperglycemia, and cravings.
• ·Medications. Certain antipsychotics, antidepressants (mirtazapine, paroxetine), corticosteroids, beta-blockers, insulin, and sulfonylureas commonly cause weight gain.
• ·Environment. Ultra-processed foods are engineered to be hyperpalatable and energy-dense; the modern food environment biases intake upward independent of intention.

Treating obesity well means identifying which of these factors are operating in a given patient — not assigning blame.

Health Risks

Health Risks of Untreated Obesity

Obesity meaningfully increases the risk of more than 60 other medical conditions [1][5]. The most clinically important include:

• ·Type 2 diabetes — roughly 80% of patients with type 2 diabetes have overweight or obesity.
• ·Cardiovascular disease, hypertension, heart failure, and stroke.
• ·Obstructive sleep apnea, which is itself an independent cardiovascular risk factor.
• ·Non-alcoholic fatty liver disease (NAFLD/MASLD), now the most common chronic liver disease in U.S. adults.
• ·Osteoarthritis of weight-bearing joints, requiring more joint replacements and limiting mobility.
• ·Infertility, menstrual dysfunction, and pregnancy complications.
• ·Depression and anxiety, with bidirectional effects.
• ·At least 13 cancers, including postmenopausal breast, endometrial, colorectal, esophageal, kidney, pancreatic, and liver cancers.

Even modest weight loss has outsized impact. A 5–10% reduction in body weight improves blood pressure, lipids, and glycemic control, and the landmark Diabetes Prevention Program showed a ~58% reduction in progression to type 2 diabetes with ~7% lifestyle-induced weight loss [6]. Losses of 15% or more, now routinely achievable with GLP-1 and dual-incretin therapy, drive remission of fatty liver disease, sleep apnea, and type 2 diabetes in many patients [2][3].

Treatment

How Is Obesity Treated?

Modern obesity care is a physician-guided spectrum, layered to the patient's biology and goals — not a one-size diet.

• ·Lifestyle medicine — first and lifelong. A Mediterranean-style or higher-protein eating pattern, 150–300 minutes per week of moderate aerobic activity, two sessions of resistance training to preserve lean mass during weight loss, 7–9 hours of sleep, and structured behavioral support form the foundation. Lifestyle alone typically produces 3–8% weight loss.
• ·GLP-1 and dual-incretin pharmacotherapy. Once-weekly semaglutide (Wegovy) produced an average ~15% weight loss in the STEP 1 trial [2]; tirzepatide (Zepbound) produced up to ~22.5% in SURMOUNT-1 [3]. These medications act on appetite-regulating circuits in the brain and gut, reduce hunger, slow gastric emptying, and improve insulin sensitivity. They are intended as long-term, chronic-disease therapy — discontinuation typically leads to weight regain.
• ·Hormone optimization. Treating hypothyroidism, low testosterone, perimenopausal estrogen loss, or PCOS-related insulin resistance can unlock progress that lifestyle and medication alone cannot.
• ·Bariatric and metabolic surgery. Sleeve gastrectomy and Roux-en-Y gastric bypass produce durable 25–35% total body weight loss and cause remission of type 2 diabetes in a large fraction of patients with class II–III obesity. Surgery is generally considered for BMI ≥35, or ≥30 with metabolic disease, after appropriate evaluation.

The right combination depends on disease severity, comorbidities, prior history, medications, and patient preference — which is why physician oversight matters.

Clinical Care

When to See a Physician

Consider a physician evaluation when any of the following are true: BMI is 30 or higher; BMI is 27 or higher with a metabolic concern (prediabetes, fatty liver, hypertension, dyslipidemia, sleep apnea); weight has trended upward despite consistent effort; weight gain is rapid or unexplained; or you are considering GLP-1 therapy.

A physician evaluation should include a metabolic workup (fasting insulin, A1c, lipid panel including ApoB, liver enzymes, TSH, and — where indicated — sex hormones and cortisol), a medication review to identify weight-promoting agents, and a discussion of lifestyle, pharmacotherapy, and surgical options sequenced to your biology.

Look for physicians board-certified through the American Board of Obesity Medicine (ABOM) or affiliated with the Obesity Medicine Association. Haute MD's Weight Loss directory features physicians who deliver this care as a long-term partnership — not a short cosmetic intervention.